Brentuximab Vedotin with Chemotherapy for CD30-Positive Peripheral T-cell Lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.

BACKGROUND: Based on the encouraging activity and manageable safety profile observed in a phase 1 study, the ECHELON-2 trial was initiated to compare the efficacy and safety of brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) versus cyclophosphamide, doxorubicin, vincristin...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Lancet
Autors principals: Horwitz, Steven, O’Connor, Owen A, Pro, Barbara, Illidge, Tim, Fanale, Michelle, Advani, Ranjana, Bartlett, Nancy L, Christensen, Jacob Haaber, Morschhauser, Franck, Domingo-Domenech, Eva, Rossi, Giuseppe, Kim, Won Seog, Feldman, Tatyana, Lennard, Anne, Belada, David, Illès, Árpád, Tobinai, Kensei, Tsukasaki, Kunihiro, Yeh, Su-Peng, Shustov, Andrei, Hüttmann, Andreas, Savage, Kerry J, Yuen, Sam, Iyer, Swaminathan, Zinzani, Pier Luigi, Hua, Zhaowei, Little, Meredith, Rao, Shangbang, Woolery, Joseph, Manley, Thomas, Trümper, Lorenz
Format: Artigo
Idioma:Inglês
Publicat: 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6436818/
https://ncbi.nlm.nih.gov/pubmed/30522922
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(18)32984-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars